Our partners at Breast Cancer Action (the only breast cancer organization as the plaintiff in the case) fought and won a tough battle against Myriad Genetics, the corporation who held a monopoly on the BRCA genes. Now research, treatment, and testing for diseases associated with these genetic links is open to all parties interested in furthering innovation for public health. Where there is competition among service providers (in any industry), the public wins, because costs for the consumer are reduced tremendously (in this case, testing for the genes), and innovation undeniably thrives.
To read more about Breast Cancer Action's victory today, visit their post and help to support their amazing work by sharing it with your friends, family, and colleagues! Thank you BCA for a job well done!